Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
BofA Securities upgraded Neptune Insurance Holdings (NYSE: NP) to Neutral from Underperform and nudged its price target up to $23, citing the insurer's revised revenue guidance. The new target, derived from a discounted cash flow model, implies roughly 11% upside from the current trading level. Analysts and other banks have recently revised ratings…
Oppenheimer raised its price target on Deere & Company to $715 from $531 and maintained an Outperform rating, citing robust construction demand, a stabilizing agricultural backdrop, and a move from negative to positive earnings revisions. The stock jumped on the news as Deere reported a significant quarterly earnings and revenue beat.
Oppenheimer increased its price target on Pulse Biosciences (PLSE) to $30 from $22 and kept an Outperform rating, citing recent commercial updates and fourth-quarter results. Pulse reported Q4 2025 revenue of $0.3 million, aligned with Oppenheimer’s estimate, while operating losses continued as operating expenses reached about $18.3 million. The co…
Britain's foreign secretary will hold talks in Washington with the U.S. Secretary of State amid a renewed flare-up over the sovereignty of the Chagos Islands and the continued operation of the joint U.S.-UK base on Diego Garcia. The dispute follows a sovereignty transfer agreed by London last year and a string of contradictory comments from the U.S…
UBS strategists identify tentative recovery signals in the UK equity market driven by improvements in banks and consumer goods. Despite recent outperformance from large caps and a rebound in the FTSE 250, UBS warns the market is an "optional" destination for global capital and recommends stock selection focused on buybacks, dividends and underowned…
Evercore ISI reduced its price target on Five9, Inc. (NASDAQ: FIVN) to $24 from $40 while keeping an Outperform rating following the company’s fourth-quarter results and updated forward guidance. Revenue growth for the quarter was 7.8% year-over-year, with management outlining 2026 and initial 2027 growth expectations that were slightly below prior…
Morgan Stanley lowered LatAm Airlines Group's rating to Equalweight from Overweight while simultaneously raising its price target to $67 from $56. Analyst Jens Spiess pointed to the stock's strong recent performance - including an 85% gain over the past year and a 31% rise in the last six months - as the rationale for taking profits and reassessing…
U.S. stock index futures were largely unchanged on Friday as traders awaited a slate of economic releases - including preliminary fourth-quarter GDP and the Personal Consumption Expenditures index - that could shape expectations for monetary policy easing. Market participants also monitored tensions between Washington and Tehran, a potential U.S. S…
Morgan Stanley identifies the persistence of trade-driven volatility as the central question for U.S. growth in 2026. Analyst Michael Gapen argues that large swings in net trade were a defining feature of 2025 and that if those swings have abated, GDP will provide a clearer reading next year. The bank flags specific import categories - computers, p…
Futures tied to Canada’s primary stock gauge rose on Friday after the S&P/TSX composite recorded a fresh record close. Strength in gold and energy underpinned gains in materials and energy sectors, while traders awaited key U.S. data on inflation and GDP and monitored strains in private credit markets.
William Blair initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating, citing revenue momentum and a strong gross margin but signaling caution around a planned U.S. commercial reorganization and its potential impact on 2026 forecasts. The stock trades at a P/E of 28 and a market capitalization of $19.67 billion.
Barclays has begun coverage of Amgen Inc. with an Equalweight rating and a $185 price target. While the firm cites solid fiscal 2026 guidance and expected momentum for Repatha after VESALIUS, analyst Carter Gould warned that the Phase 3 MARITIME trial readout is far off, leaving important questions unresolved. Market observers show divergent views …
William Blair launched coverage of Stryker Corporation (NYSE: SYK) with an Outperform rating, pointing to the medical technology company's diversified product mix, recent acquisitions and margin profile. The firm highlighted Stryker's expansion into new clinical areas and data-driven offerings, while noting international expansion and ambulatory su…
Barclays has initiated coverage of Gilead Sciences Inc. with an Equalweight rating and a $155 price target, citing a return to the company’s infectious-disease focus but noting that recent share gains and valuation compress the upside. Gilead’s Q4 2025 results topped expectations and several peers raised targets, while others remained cautious.
Barclays has begun coverage of Pfizer Inc. with an underweight rating and a $25 price target, pointing to imminent patent expirations and a company emphasis on reducing leverage. The bank expects limited share movement until clinical and pipeline updates arrive, even as other firms maintain higher price targets and Pfizer posts stronger-than-expect…
Barclays has initiated coverage of Biogen Inc. with an Equalweight rating and a $185.00 price target. Analyst Carter Gould cited tangible commercial and pipeline improvements but tempered upside until more pipeline data arrives. The stock currently trades above the new target, and recent fourth-quarter results and revisions from other firms have dr…
Barclays initiated coverage of Merck & Co. (MRK) with an overweight rating and set a $140 price target, pointing to a slate of product launches and clinical readouts expected to materialize in 2026. The firm emphasized the potential impact of enlicitide - the first oral PCSK9 inhibitor - and pivotal data from tulisokibart’s ATLAS-UC study, the …
Barclays has initiated coverage of Bristol-Myers Squibb Co. (NYSE: BMY) with an overweight rating and a $75 price target, implying roughly 24% upside from the current $60.30 share price. The broker highlights early signs of progress in the company’s pipeline as it prepares for looming patent expirations on Eliquis and Opdivo, and anticipates upward…
Barclays has initiated coverage of Eli Lilly with an overweight rating and a $1,350 price target, pointing to the company’s leading role in the expanding obesity treatment market driven by GLP-1 therapies. The bank framed medical treatment of obesity as a structural shift and defended Lilly’s premium valuation against broader pharmaceutical peers. …
Barclays has begun coverage of AbbVie Inc. with an overweight rating and a $275.00 price target, highlighting the company's potential for operating leverage that the market may not yet fully price. The target implies roughly 23% upside from a reference quote of $224.35. The bank expects 2026 will offer a series of proof-of-concept data readouts acr…
A mixed holiday schedule left markets navigating a volatile week in which crude oil jumped to its highest level since August amid rising Gulf tensions. At the same time, signs of stronger US manufacturing and labour data have supported demand expectations, while heavy AI investment plans among major technology firms and circular capital flows are p…
Global equity funds recorded their biggest weekly net inflow in five weeks during the seven days to February 18, receiving $36.33 billion as risk appetite broadened beyond artificial intelligence names and hopes for Federal Reserve rate cuts improved. European funds led regional flows while U.S. and Asian funds also drew substantial purchases. Bond…
Shares of BE Semiconductor Industries regained ground on Friday, rising more than 4% after Morgan Stanley reiterated its bullish view following a guidance-related selloff. The Dutch equipment maker reported results and guidance broadly in line with expectations, but a lack of upside prompted an earlier 7.5% one-day drop. Morgan Stanley kept its inv…
Huntsman (HUN) trades at a sub-1x price-to-book and roughly 0.4x price-to-sales while producing meaningful free cash flow. A $0.0875/share dividend and secular demand tailwinds in polyurethanes, TPU and amines create a favorable entry for patient investors. This trade idea lays out an entry, stop and target across time horizons and highlights the o…
Piper Sandler is advising investors to exercise restraint following a constructive but fragile market rebound. The firm highlights that key indexes remain below their 50-day moving averages, momentum measures are cooling, and recent gains have shown limited follow-through. Energy stands out as a relative leader, supported by crude oil's setup near …
